CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Climb Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$9.73−0.09 (-0.92%)
Close on Oct 19, 2026
- Market cap
- $740.98M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$7.80 (+404.1%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $740.98M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.09
- Dividend yield
- –
- Free cash flow yield
- -7.36%
Fundamentals
- Net income
- -$57.62M
- EPS, diluted
- -$0.83
- Free cash flow
- -$54.54M
- Book value per share
- $3.15
- Diluted shares
- 76M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$64.76M
Net income
-$57.62M
EPS, diluted
-$0.83
Free cash flow
–
Reported periodTrailing twelve months